Drug Information

Drug General Information
Drug ID
D05KQC
Former ID
DNC011731
Drug Name
DNQX
Drug Type
Small molecular drug
Indication Discovery agent Investigative [529309]
Structure
Download
2D MOL

3D MOL
Formula
C8H4N4O6
Canonical SMILES
C1=C2C(=CC(=C1[N+](=O)[O-])[N+](=O)[O-])NC(=O)C(=O)N2
InChI
1S/C8H4N4O6/c13-7-8(14)10-4-2-6(12(17)18)5(11(15)16)1-3(4)9-7/h1-2H,(H,9,13)(H,10,14)
InChIKey
RWVIMCIPOAXUDG-UHFFFAOYSA-N
CAS Number
CAS 2379-57-9
PubChem Compound ID
3899541
Target and Pathway
Target(s) Glutamate receptor 1 Target Info Inhibitor [534261]
Glutamate receptor, ionotropic kainate 1 Target Info Inhibitor [534261]
Glutamate [NMDA] receptor subunit epsilon 2 Target Info Inhibitor [529309]
Glutamate receptor AMPA subtype Target Info Inhibitor [534261]
Glutamate [NMDA] receptor subunit epsilon 1 Target Info Inhibitor [529309]
NMDA receptor subunit NR1 Target Info Inhibitor [529309]
KEGG Pathway cAMP signaling pathway
Neuroactive ligand-receptor interaction
Circadian entrainment
Long-term potentiation
Retrograde endocannabinoid signaling
Glutamatergic synapse
Dopaminergic synapse
Long-term depression
Amyotrophic lateral sclerosis (ALS)
Amphetamine addiction
Nicotine addictionhsa04080:Neuroactive ligand-receptor interaction
Glutamatergic synapsehsa04014:Ras signaling pathway
Rap1 signaling pathway
Alzheimer's disease
Huntington's disease
Cocaine addiction
Nicotine addiction
Alcoholism
Systemic lupus erythematosushsa04014:Ras signaling pathway
Calcium signaling pathway
PANTHER Pathway Ionotropic glutamate receptor pathway
Metabotropic glutamate receptor group III pathwayP00029:Huntington disease
Metabotropic glutamate receptor group III pathway
Metabotropic glutamate receptor group I pathwayP00029:Huntington disease
Metabotropic glutamate receptor group I pathway
Muscarinic acetylcholine receptor 1 and 3 signaling pathwayP00029:Huntington disease
Muscarinic acetylcholine receptor 1 and 3 signaling pathway
Pathway Interaction Database EPHB forward signalingerbb4_pathway:ErbB4 signaling events
Reelin signaling pathwayreelinpathway:Reelin signaling pathway
Reactome COPII (Coat Protein 2) Mediated Vesicle Transport
Trafficking of AMPA receptors
Trafficking of GluR2-containing AMPA receptors
Unblocking of NMDA receptor, glutamate binding and activation
Cargo concentration in the ERR-HSA-3928662:EPHB-mediated forward signaling
CREB phosphorylation through the activation of CaMKII
Ras activation uopn Ca2+ infux through NMDA receptor
RAF/MAP kinase cascadeR-HSA-438066:Unblocking of NMDA receptor, glutamate binding and activation
RAF/MAP kinase cascadeR-HSA-3928662:EPHB-mediated forward signaling
RAF/MAP kinase cascade
WikiPathways Hypothetical Network for Drug Addiction
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
Amyotrophic lateral sclerosis (ALS)
BDNF signaling pathwayWP2754:Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic CellWP666:Hypothetical Network for Drug Addiction
BDNF signaling pathwayWP666:Hypothetical Network for Drug Addiction
Alzheimers DiseaseWP706:SIDS Susceptibility Pathways
Spinal Cord Injury
BDNF signaling pathway
Alzheimers Disease
References
Ref 529309J Med Chem. 1991 Apr;34(4):1243-52.Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor.
Ref 529309J Med Chem. 1991 Apr;34(4):1243-52.Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor.
Ref 534261J Med Chem. 1996 Oct 25;39(22):4430-8.Synthesis of chiral 1-(2'-amino-2'-carboxyethyl)-1,4-dihydro-6,7-quinoxaline-2,3-diones: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor agonists and antagonists.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.